Benitec Biopharma Inc.

Benitec Biopharma Inc.

BNTC·NASDAQ

$10.70

+1.1%
HealthcareBiotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

At a Glance

Live Snapshot
Market Cap$280.84M
EPS-1.0500
P/E Ratio-10.19
Earnings Date09/28/2026

bntc

Other Financing Activities

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Benitec Biopharma Inc.

Benitec Biopharma Inc. Competitors Analysis of Other Financing Activities

BNTC · NASDAQ
CompanyOther Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
IMAB logo
I-Mab
NASDAQ:IMAB
0.00
N/AN/AN/A
0.00
N/AN/AN/A
-400.00K
N/AN/AN/A
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
-88.34M
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
0.00
N/AN/AN/A
845.00K
N/A-16.0%N/A
-16.00K
N/AN/AN/A
-4.39M
N/AN/AN/A
0.00
N/AN/AN/A
Benitec Biopharma Inc.

Benitec Biopharma Inc. Fair Value Envelope

BNTC · NASDAQ

Our analysis suggests that BNTC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.7, this represents a potential HIDDEN relative to our calculated worth for Benitec Biopharma Inc..

Intrinsic Value
Current Price: $10.7